Biotech Showcase™ 2016: Interview: Keryx reboots disappointing product launch

February 26, 2016
Keryx Biopharmaceuticals CEO Greg Madison reveals to Mike Ward, global director of content for Informa's pharma insights portfolio, how the company turned around what was initially a disappointing launch of the company's first product. Auryxia (ferric citrate) was first launched in 2015 for the control of serum phosphorus levels in dialysis patients with chronic kidney disease. However, as Madison notes, the launch got off to a rough start with slow sales and a chorus of naysayers. Madison explains how the company revisited its launch strategy, resulting in an increase in sales. The company is now looking at a potential label extension in the US, based on data from a Phase III pivotal study evaluating Auryxia in pre-dialysis patients with iron deficiency anemia—topline results expected in 2Q 2016—and expects to identify a partner for the European market after being granted a strong label for EU marketing authorization in 2015. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview: TLC delivers sustained release and improved tissue targeting
Biotech Showcase™ 2016: Interview: TLC delivers sustained release and improved tissue targeting

Ensuring difficult-to-deliver drugs get to target sites is a common challenge for many pharma and biotech c...

Next Video
Biotech Showcase™ 2016: Interview: Ergomed pursues shared-risk approach to help VC-backed biotechs
Biotech Showcase™ 2016: Interview: Ergomed pursues shared-risk approach to help VC-backed biotechs

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-deve...